Simpson Thacher recently represented the initial purchasers in connection with an offering of Notes by Roche Holdings, Inc. (“Roche”). The offering consisted of a Rule 144A and Regulation S offering of U.S.$500,000,000 aggregate principal amount of 4.075% notes due 2030, U.S.$600,000,000 aggregate principal amount of 4.374% notes due 2032 and U.S.$800,000,000 aggregate principal amount of 4.666% notes due 2035 together, the “Notes”). The offering closed on December 2, 2025.
The net proceeds from the issuance of the Notes will be used for general corporate purposes, including, among others, mergers and acquisitions, licensing, refinancing of regular debt maturities, payments of dividends and potential early redemptions. The Roche Group is one of the world’s leading suppliers of in vitro diagnostics, one of the world’s largest biotech companies and a leading provider of cancer treatment drugs worldwide.
The Simpson Thacher team included Mark Brod, Ziang Zhou and Lampros Anastasopoulos (Capital Markets); Vanessa Burrows, Jacob Madden and Alison Peters (Healthcare), Jonathan Cantor and Jemma Li (Tax), Ron Ben-Yehuda and Christina Breitbeil (IP) and Michael Isby (Environmental).